Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugssierra health and life infliximab IV Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedsierra health and lifePolicy 2026D0004AR

    Infliximab (IV) products — coverage criteria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0004AR alerts

    Get alerted when Policy 2026D0004AR changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for intravenous infliximab products (including specified biosimilars) across multiple indications for Sierra Health and Life members. Applies to providers requesting coverage under the medical benefit unless the product is self-administered subcutaneous infliximab obtained under pharmacy benefit as noted.

    Policy Summary
    Payersierra health and life
    PolicyInfliximab (IV) products — coverage criteria
    Policy CodePolicy 2026D0004AR
    Change TypeRemoved multiple indication-specific criteriaupdated terminology and prior/combination therapy lists
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with applicable ICD-10 diagnosis code and documentation of prior therapy or intolerance when requesting non-preferred infliximab.
    SourceLink
    POLICY UPDATE CHANGES

    Removed coverage criteria for proven treatment of ankylosing spondylitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.

    Replaced references to 'targeted immunomodulator' with 'systemic targeted immunomodulator' in medical necessity criteria.

    Updated lists of systemic targeted immunomodulators that must not be used in combination with infliximab and lists of prior U.S. FDA–approved systemic targeted immunomodulators for initial therapy across multiple indications (adds and removes multiple specific agents).

    Added criterion requiring diagnosis of an immune checkpoint inhibitor-related toxicity for that indication.

    Removed HCPCS code Q5109.

    Removed Documentation Requirements section from the policy.

    6Indications removed
    Inflectra, AvsolaPreferred products
    Remicade, RenflexisNon-preferred products
    12 monthsTypical chronic approval
    14 wksTrial before non-preferred
    4 dosesAcute GVHD/ICI limit

    Coverage Criteria and Medical Necessity

    Preferred Product Criteria

    Coverage for non-preferred infliximab products (e.g., Remicade, Renflexis) is medically necessary when BOTH of the following are met:

    Non-preferred infliximab approval: 1) Either: (a) Documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response and residual disease activity AND physician attestation that the clinical response would be expected to be superior with the non-preferred infliximab product (e.g., Remicade, Renflexis), OR (b) Documentation of intolerance, contraindication, or adverse event to Inflectra or Avsola AND physician attestation that the same intolerance/contraindication/adverse event would not be expected with the non-preferred infliximab product; AND 2) Patient has not had loss of a favorable response after established maintenance therapy with Inflectra, Avsola, or another infliximab biosimilar product.14 weeks trial

    Used to approve non-preferred products

    Ankylosing Spondylitis

    Infliximab is medically necessary for ankylosing spondylitis when ALL of the following are met:

    Policy Summary
    Payersierra health and life
    PolicyInfliximab (IV) products — coverage criteria
    Policy CodePolicy 2026D0004AR
    Change TypeRemoved multiple indication-specific criteriaupdated terminology and prior/combination therapy lists
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with applicable ICD-10 diagnosis code and documentation of prior therapy or intolerance when requesting non-preferred infliximab.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityInitial Authorization RequirementsContinuation / Reauthorization RequirementsStep Therapy and Prior Authorization ConditionsBilling and Diagnosis CodesProvider Actions, Prior Authorization & DocumentationBiosimilars and Product PreferenceSite of Care and AdministrationBackground and DefinitionsPolicy Overview and Key MetricsPolicy Changes and Revision History
    Initial therapy for AS:
    Diagnosis of ankylosing spondylitis; AND one of: (a) history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks unless contraindicated, OR (b) prior treatment with an FDA‑approved systemic targeted immunomodulator for ankylosing spondylitis, OR (c) patient is currently on infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for ankylosing spondylitis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND prescribed by or in consultation with a rheumatologist; AND initial authorization for no more than 12 months.
    NSAIDs each ≥4 weeks
    Continuation therapy for AS: Documentation of positive clinical response to infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for ankylosing spondylitis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.

    Crohn's disease

    Infliximab is medically necessary for Crohn's disease when ALL of the following are met:

    Initial therapy for Crohn's disease: Diagnosis of moderately to severely active Crohn's disease; AND disease considered high risk (e.g., fistulizing, stricturing, luminal, perianal, extensive disease, growth delay); AND one of: history of failure to one conventional therapy at maximally indicated doses (e.g., corticosteroids, 6‑mercaptopurine, azathioprine, methotrexate) unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for Crohn's disease, OR patient is currently on infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for Crohn's disease; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND prescribed by or in consultation with a gastroenterologist; AND initial authorization for no more than 12 months.
    Continuation therapy for Crohn's disease: Documentation of positive clinical response to infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for Crohn's disease; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.

    Noninfectious uveitis

    Infliximab is medically necessary for refractory noninfectious uveitis causing or threatening vision loss when ALL are met:

    Initial therapy for noninfectious uveitis: Diagnosis of refractory noninfectious uveitis that is causing or threatening vision loss; AND history of failure, contraindication, or intolerance to topical corticosteroids AND systemic corticosteroids AND immunosuppressive drugs (e.g., azathioprine, cyclosporine, methotrexate); AND infliximab dosed no higher than 5 mg/kg administered at week 0, 2, 6, then every 8 weeks thereafter; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same condition; AND prescribed by or in consultation with a rheumatologist or ophthalmologist; AND initial authorization for no more than 12 months.<= 5 mg/kg starting schedule
    Continuation therapy for noninfectious uveitis: Documentation of positive clinical response to infliximab; AND infliximab dosed no higher than 5 mg/kg every 8 weeks; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same condition; AND reauthorization for no more than 12 months.

    Plaque psoriasis

    Infliximab is medically necessary for chronic severe plaque psoriasis when ALL are met:

    Initial therapy for plaque psoriasis: Diagnosis of chronic severe plaque psoriasis (extensive and/or disabling); AND one of: (a) ≥3% body surface area involvement or palmoplantar/facial/genital/scalp involvement AND history of failure to one topical therapy unless contraindicated AND history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated, OR (b) prior treatment with an FDA‑approved systemic targeted immunomodulator for plaque psoriasis, OR (c) patient is currently on infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for plaque psoriasis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND prescribed by or in consultation with a dermatologist; AND initial authorization for no more than 12 months.
    Continuation therapy for plaque psoriasis: Documentation of positive clinical response to infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for plaque psoriasis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.

    Psoriatic arthritis

    Infliximab is medically necessary for psoriatic arthritis when ALL are met:

    Initial therapy for PsA: Diagnosis of psoriatic arthritis; AND one of: history of failure to a 3‑month trial of methotrexate at maximally indicated dose unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for psoriatic arthritis, OR patient is currently on infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for psoriatic arthritis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND prescribed by or in consultation with a rheumatologist or dermatologist; AND initial authorization for no more than 12 months.
    Continuation therapy for PsA: Documentation of positive clinical response to infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for psoriatic arthritis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.

    Rheumatoid arthritis

    Infliximab is medically necessary for rheumatoid arthritis when ALL are met:

    Initial therapy for RA: Diagnosis of moderately to severely active rheumatoid arthritis; AND one of: history of failure or intolerance to a 3‑month trial of one non‑biologic DMARD at maximally indicated doses within the last 6 months unless contraindicated, OR prior treatment with an FDA‑approved systemic targeted immunomodulator for rheumatoid arthritis, OR patient is currently on infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for rheumatoid arthritis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND prescribed by or in consultation with a rheumatologist; AND initial authorization for no more than 12 months.
    Continuation therapy for RA: Documentation of positive clinical response to infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for rheumatoid arthritis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.

    Sarcoidosis

    Infliximab is medically necessary for sarcoidosis when ALL are met:

    Initial therapy for sarcoidosis: Diagnosis of sarcoidosis; AND history of failure, contraindication, or intolerance to corticosteroids; AND history of failure, contraindication, or intolerance to one immunosuppressant (e.g., methotrexate, cyclophosphamide, azathioprine); AND infliximab dosed no higher than 10 mg/kg administered at week 0, 2, then once every 4 to 6 weeks thereafter; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND initial authorization for no more than 12 months.≤ 10 mg/kg
    Continuation therapy for sarcoidosis: Documentation of positive clinical response to infliximab; AND infliximab dosed no higher than 10 mg/kg every 4 to 6 weeks; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.≤ 10 mg/kg

    Rheumatoid arthritis — initial and continuation

    Rheumatoid arthritis — initial and continuation

    Initial therapy: Diagnosis of rheumatoid arthritis; infliximab dosed according to U.S. FDA labeled dosing for rheumatoid arthritis; patient not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; prescribed by or in consultation with a rheumatologist; initial authorization for no more than 12 months.
    Continuation of therapy: Documentation of positive clinical response to infliximab; infliximab dosed according to U.S. FDA labeled dosing for rheumatoid arthritis; patient not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; reauthorization for no more than 12 months.

    Sarcoidosis — initial and continuation

    Sarcoidosis — initial and continuation

    Initial therapy: Diagnosis of sarcoidosis; history of failure, contraindication, or intolerance to corticosteroids; history of failure, contraindication, or intolerance to one immunosuppressant (e.g., methotrexate, cyclophosphamide, azathioprine); infliximab dosed no higher than 10 mg/kg administered at week 0, 2, then once every 4 to 6 weeks thereafter; patient not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; initial authorization for no more than 12 months.≤10 mg/kg
    Continuation of therapy: Documentation of positive clinical response to infliximab; infliximab dosed no higher than 10 mg/kg administered every 4 to 6 weeks; patient not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; reauthorization for no more than 12 months.≤10 mg/kg

    Ulcerative colitis — initial and continuation

    Ulcerative colitis — initial and continuation criteria

    Initial therapy: Diagnosis of moderately to severely active ulcerative colitis; AND one of: history of failure, contraindication, or intolerance to at least one conventional therapy (e.g., 6‑mercaptopurine, aminosalicylate, azathioprine, corticosteroids), OR prior treatment with an FDA‑approved systemic targeted immunomodulator for ulcerative colitis, OR patient is currently on infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for ulcerative colitis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND prescribed by or in consultation with a gastroenterologist; AND initial authorization for no more than 12 months.
    Continuation of therapy: Documentation of positive clinical response to infliximab; AND infliximab dosed according to U.S. FDA labeled dosing for ulcerative colitis; AND patient is not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; AND reauthorization for no more than 12 months.

    Acute GVHD — initial and continuation

    Acute GVHD — initial and continuation criteria

    Initial therapy: Diagnosis of steroid‑refractory acute graft‑versus‑host disease (GVHD); AND one of: patient is receiving infliximab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; AND initial authorization for no more than 4 doses.
    Continuation of therapy: Documentation of positive clinical response; patient continues to experience acute GVHD; AND one of: patient is receiving infliximab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; AND reauthorization for no more than 4 doses.

    ICI-related toxicities — initial and continuation

    ICI-related toxicities — initial and continuation criteria

    Initial therapy: Recent receipt of checkpoint inhibitor therapy; AND diagnosis of an immune checkpoint inhibitor‑related toxicity; AND inadequate improvement despite systemic corticosteroid therapy of adequate dose and duration for the specific severity and diagnosis; AND one of: patient is receiving infliximab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; AND initial authorization for no more than 4 doses.
    Continuation of therapy: Documentation of positive clinical response; patient continues to experience toxicities from checkpoint inhibitor therapy; AND one of: patient is receiving infliximab in combination with systemic corticosteroids OR patient is intolerant to systemic corticosteroid therapy; AND reauthorization for no more than 4 doses.

    Covered indications (FDA and NCCN-supported)

    Infliximab is considered proven/covered for the following indications when clinical criteria are met:

    FDA‑approved indications: Crohn's disease (adult and pediatric ≥6), ulcerative colitis (adult and pediatric ≥6), rheumatoid arthritis (in combination with methotrexate), plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and fistulizing Crohn's disease.
    NCCN recommended uses: Selected NCCN (2A) recommendations include steroid‑refractory acute GVHD and certain immune checkpoint inhibitor‑related toxicities (e.g., severe GI inflammation, steroid‑refractory uveitis, myocarditis) when criteria are met.

    Limited evidence / off-label indications

    Uses supported by smaller trials, trials with mixed results, or limited evidence:

    Sarcoidosis: Randomized trial showed a small improvement in FVC at 24 weeks for infliximab versus placebo; additional small studies support use in treatment‑resistant sarcoidosis.
    Juvenile idiopathic arthritis: Randomized trial data were mixed and did not demonstrate clear efficacy for the lower dose; safety concerns noted; larger studies are needed.
    Miscellaneous off‑label uses: Small open‑label studies and case reports suggest benefit in conditions such as adult‑onset Still's disease, Sjögren's syndrome, hidradenitis suppurativa, and others but robust controlled trial evidence is lacking; coverage depends on member benefits and state mandates.

    Immune Checkpoint Inhibitor-Related Toxicities

    Updated criterion for immune checkpoint inhibitor-related toxicity

    Immune checkpoint inhibitor‑related toxicity: Patient has a diagnosis of an immune checkpoint inhibitor‑related toxicity.

    Replaced prior severity‑specific initial therapy requirements; steroid‑failure wording requires inadequate improvement despite corticosteroid therapy of adequate dose and duration for the specific severity and diagnosis.

    Terminology and Prior/Combination Therapy Requirements

    Revised medical necessity criterion language and prior therapy/combination restrictions across multiple indications

    Terminology update: References to 'targeted immunomodulator' have been replaced with 'systemic targeted immunomodulator' across medical necessity criteria.
    Combination therapy exclusions per indication: For each indication the patient must not be receiving specified systemic targeted immunomodulators in combination with infliximab for the same indication; the lists of disallowed combination agents and prior targeted therapies were updated (examples vary by indication).

    See per‑indication lists in the policy for the updated agent examples.

    Self-administered subcutaneous infliximab (for example, Zymfentra/infliximab-dyyb) is dispensed under the pharmacy benefit unless the member's benefit plan documents specify otherwise. Exception: certain delegated UnitedHealthcare of California reviews may route the self-administered product under the medical benefit. Prior authorization is required for medical‑benefit intravenous infliximab products, and Inflectra and Avsola are identified as preferred infliximab products; non‑preferred products (e.g., Remicade, Renflexis) require additional documented justification per policy (see preferred product criteria and step therapy rules).

    The policy designates certain uses of infliximab as unproven and not medically necessary. Listed examples include hidradenitis suppurativa, juvenile idiopathic arthritis (juvenile rheumatoid arthritis), myelodysplastic syndromes, and Reiter's syndrome. Small open‑label studies or case reports exist for a variety of other conditions, but the policy considers these indications unproven in the absence of large, randomized controlled trials.

    When requesting coverage or submitting a prior authorization, providers must include an applicable ICD‑10 diagnosis code from the policy's listed codes that supports medical necessity for the requested infliximab service or administration.

    Experimental, investigational, or unproven uses of infliximab may be excluded from coverage unless the member's specific Certificate of Coverage permits such treatments or a state mandate requires coverage. Always consult the member's benefit document and applicable federal/state mandates when making coverage determinations.

    The policy was revised to remove coverage criteria that previously listed certain conditions as proven treatment indications. Requests for infliximab for the following removed indications — ankylosing spondylitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis — may be denied or require alternate review per the updated policy and the member's benefit terms.

    Indications designated as unproven are labeled not medically necessary because available randomized controlled trial data are insufficiently robust to demonstrate clear superiority in clinical efficacy; therefore the policy does not consider routine use of infliximab for these conditions to be medically necessary in the absence of stronger evidence or specific benefit coverage allowances.

    The policy cites specific examples where evidence is limited or conflicting. For example, a randomized controlled pediatric trial of infliximab for juvenile idiopathic arthritis failed to show statistically significant benefit for the 3 mg/kg dose and raised safety concerns; other indications are supported only by small open‑label studies or case series. These limitations underpin the policy's classification of those uses as unproven.

    Operationally, indications that were removed from the coverage criteria table are no longer listed as proven treatment criteria in this policy version; providers should not assume continued coverage under the criteria and must follow the updated policy language and the member's specific plan for coverage determination.

    Initial Authorization Requirements

    Initial Therapy

    Initial Therapy — General initial authorization requirements vary by indication (diagnosis, prior therapy failure/prior targeted therapy, dosing limits).

    General initial therapy requirements: Initial authorization requires documentation of the indicated diagnosis, applicable prior therapy failure or prior targeted immunomodulator use as specified per indication, dosing consistent with U.S. FDA labeling (or indication‑specific maximum dosing where stated), prescriber specialty or consultation as specified (e.g., rheumatologist, gastroenterologist, dermatologist, ophthalmologist), and initial authorization limited to no more than 12 months for chronic indications (or up to 4 doses for acute GVHD and ICI‑related toxicities).

    Initial therapy rules

    Initial therapy rules — Operational rules and variation by indication.

    Per‑indication initial rules: See indication‑specific criteria: prior therapy requirements (e.g., NSAID trials for AS; conventional therapy or prior targeted immunomodulator for IBD; corticosteroid and immunosuppressant failure for uveitis and sarcoidosis), specialist prescriber or consultation requirements, prohibition on concurrent systemic targeted immunomodulator for the same indication, and specified initial authorization durations (commonly ≤12 months; acute indications ≤4 doses).

    Initial therapy indications

    Initial therapy indications — FDA‑labeled initial uses

    FDA‑labeled initial uses: Infliximab is FDA‑approved for induction and maintenance in moderately to severely active Crohn's disease and ulcerative colitis (adult and pediatric ≥6), rheumatoid arthritis (with methotrexate), plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and fistulizing Crohn's disease.

    Initial therapy — Immune checkpoint inhibitor-related toxicity

    Initial therapy — Immune checkpoint inhibitor-related toxicity requirement

    ICI initial requirement: Patient must have a diagnosis of an immune checkpoint inhibitor‑related toxicity and have had inadequate improvement despite systemic corticosteroid therapy of adequate dose and duration for the specific severity and diagnosis to qualify for initial infliximab therapy for this indication.

    Continuation / Reauthorization Requirements

    Continuation Therapy

    Continuation Therapy — Continuation (reauthorization) requirements are consistent across indications

    General continuation requirements: Documentation of positive clinical response to infliximab; dosing consistent with U.S. FDA labeled dosing for the indication (or specified maximum dosing where stated); patient not receiving infliximab in combination with a systemic targeted immunomodulator for the same indication; reauthorization limited to no more than 12 months for chronic indications (commonly) or up to 4 doses for acute indications (e.g., acute GVHD, ICI‑related toxicities).

    Continuation therapy requirements

    Continuation therapy requirements — Operational continuation requirements across indications.

    Operational continuation requirements: For reauthorization provide evidence of positive clinical response, continued dosing consistent with labeling or indication‑specific limits (e.g., ≤10 mg/kg for sarcoidosis; ≤5 mg/kg for uveitis), documentation that infliximab is not combined with a systemic targeted immunomodulator for the same indication, and requests should not exceed established duration limits (commonly 12 months for chronic indications; up to 4 doses for acute indications).

    Continuation therapy evidence

    Continuation therapy evidence — Long‑term/continuation therapy observations from uveitis studies:

    Uveitis long‑term observations: Long‑term infliximab treatment reduced ocular attack frequency and improved best‑corrected visual acuity in many patients; relapse occurred in about 59% with ~80% of relapses within one year, most relapses managed by corticosteroid adjustments or infusion interval changes; treatment was continued in ~85% of patients with ~15% discontinuation due to adverse effects or insufficient efficacy.

    Step Therapy and Prior Authorization Conditions

    RequirementDetails
    Preferred-product trial requirement
    Documentation of a trial of at least 14 weeks of Inflectra (infliximab-dyyb) or Avsola (infliximab-axxq) with minimal clinical response and residual disease activity; AND physician attestation that clinical response would be expected to be superior with the requested non-preferred infliximab (e.g., Remicade, Renflexis)
    Intolerance/contraindication alternative
    Documentation of intolerance, contraindication, or adverse event to Inflectra or Avsola; AND physician attestation that the same intolerance/contraindication/adverse event would not be expected with the requested non-preferred infliximab product
    Continuation condition
    Member already receiving non-preferred infliximab must change to Inflectra or Avsola unless criteria above are met to continue non-preferred product
    Indication groupPrior therapy / step required
    Sarcoidosis
    History of failure, contraindication, or intolerance to corticosteroids; AND history of failure, contraindication, or intolerance to one immunosuppressant (e.g., methotrexate, cyclophosphamide, azathioprine)
    Ulcerative colitis
    History of failure, contraindication, or intolerance to at least one conventional therapy (e.g., 6‑mercaptopurine, aminosalicylate, azathioprine, corticosteroids) OR prior treatment with a systemic targeted immunomodulator FDA‑approved for UC (document drug, date, duration) OR patient currently on infliximab
    Ankylosing spondylitis
    History of failure to two NSAIDs each used ≥4 weeks at maximally indicated doses unless contraindicated; OR prior treatment with an FDA‑approved systemic targeted immunomodulator for AS; OR current infliximab use
    NCCN-recommended useRequired prior therapy before infliximab
    Steroid-refractory acute GVHD
    Recommended after inadequate response to systemic corticosteroids (steroid‑refractory); often used in conjunction with original immunosuppressive agent per NCCN
    Immune checkpoint inhibitor-related toxicities (e.g., steroid‑refractory uveitis, severe GI inflammation, myocarditis, pneumonitis)
    Consider adding infliximab when there is inadequate improvement despite appropriate systemic corticosteroid therapy (NCCN guidance specifies timeframes such as 24–72 hours for select toxicities) — i.e., after failure/inadequate response to first‑line corticosteroids
    Stage 3 AKI related to checkpoint inhibitors
    Consider infliximab if toxicity remains > stage 2 after 4–6 weeks of corticosteroids or if creatinine worsens during steroid taper
    ProgramRequirement / Note
    Medicare Part B Step Therapy Programs
    Preferred therapy criteria and Medicare Part B step therapy programs may apply for Medicare Advantage members; follow Medicare Part B Step Therapy Programs where specified (refer to applicable LCDs/LCAs and Medicare Benefit Policy Manual guidance)

    Billing and Diagnosis Codes

    HCPCS / J-codesHCPCS
    J1745Injection, infliximab, excludes biosimilar, 10 mg.
    Q5103Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg.
    Q5104Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg.
    Q5121Injection, infliximab-axxq, biosimilar, (Avsola), 10 mg.
    ICD-10: Ophthalmologic, GI, Cardiac, Respiratory, Fistula and related (neutral)ICD-10
    D89.810Acute graft-versus-host disease.
    H20.041Secondary noninfectious iridocyclitis, right eye.
    H20.042Secondary noninfectious iridocyclitis, left eye.
    H20.043Secondary noninfectious iridocyclitis, bilateral.
    H20.049Secondary noninfectious iridocyclitis, unspecified eye.
    H20.10Chronic iridocyclitis, unspecified eye.
    H20.11Chronic iridocyclitis, right eye.
    H20.12Chronic iridocyclitis, left eye.
    H20.13Chronic iridocyclitis, bilateral.
    H20.821Vogt-Koyanagi syndrome, right eye.
    1–10 of 24
    1/3
    ICD-10: Fistula, Psoriasis, and Select Rheumatologic Codes (neutral)ICD-10
    K50.011Crohn's disease of small intestine with rectal bleeding.
    K50.013Crohn's disease of small intestine with fistula.
    K50.113Crohn's disease of large intestine with fistula.
    K50.813Crohn's disease of both small and large intestine with fistula.
    K51.313Ulcerative (chronic) rectosigmoiditis with fistula.
    K51.413Inflammatory polyps of colon with fistula.
    K51.513Left sided colitis with fistula.
    K51.813Other ulcerative colitis with fistula.
    K51.913Ulcerative colitis, unspecified with fistula.
    K60.311Anal fistula, simple, initial.
    1–10 of 18
    1/2
    ICD-10: Rheumatologic (M05-M06 range) — REQUIRED LIST (neutral)ICD-10
    M05.631Rheumatoid arthritis of right wrist with involvement of other organs and systems.
    M05.632Rheumatoid arthritis of left wrist with involvement of other organs and systems.
    M05.639Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems.
    M05.641Rheumatoid arthritis of right hand with involvement of other organs and systems.
    M05.642Rheumatoid arthritis of left hand with involvement of other organs and systems.
    M05.649Rheumatoid arthritis of unspecified hand with involvement of other organs and systems.
    M05.651Rheumatoid arthritis of right hip with involvement of other organs and systems.
    M05.652Rheumatoid arthritis of left hip with involvement of other organs and systems.
    M05.659Rheumatoid arthritis of unspecified hip with involvement of other organs and systems.
    M05.661Rheumatoid arthritis of right knee with involvement of other organs and systems.
    1–10 of 164
    1/17
    ICD-10: Additional diagnosis codes (neutral)ICD-10
    M06.861Other specified rheumatoid arthritis, right knee.
    M06.862Other specified rheumatoid arthritis, left knee.
    M06.869Other specified rheumatoid arthritis, unspecified knee.
    M06.871Other specified rheumatoid arthritis, right ankle and foot.
    M06.872Other specified rheumatoid arthritis, left ankle and foot.
    M06.879Other specified rheumatoid arthritis, unspecified ankle and foot.
    M06.88Other specified rheumatoid arthritis, vertebrae.
    M06.89Other specified rheumatoid arthritis, multiple sites.
    M06.8AOther specified rheumatoid arthritis, other specified site.
    M06.9Rheumatoid arthritis, unspecified.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for medical benefit infliximab products. Submit prior authorization requests with clinical documentation supporting the diagnosis and prior therapy history. Include dosing, treatment response, and rationale when requesting a non-preferred infliximab product (e.g., Remicade, Renflexis) such as documentation of a trial of at least 14 weeks of a preferred product (Inflectra or Avsola) with minimal response, or documentation of intolerance/contraindication to preferred products.

    • Preferred products: Inflectra (infliximab-dyyb) and Avsola (infliximab-axxq).
    • Non-preferred examples: Remicade (infliximab), Renflexis (infliximab-abda), other infliximab biosimilars.
    Denial Risk

    Diagnosis Coding Required — Missing or Mismatched Codes May Cause Denial

    Requests must include an applicable ICD-10 diagnosis code from the policy's list of covered/acceptable diagnoses. Claims or authorizations submitted without a listed applicable ICD-10 code may be denied.

    • Provider must document diagnosis using one of the applicable ICD-10 codes included in the policy.
    • Diagnosis-code mismatch or omission may trigger denial of authorization or claim.
    Documentation Required

    Required Clinical Documentation and Prior Therapy History

    For many indications, prior authorization requires documentation of prior therapies: history of failure, contraindication, or intolerance to specified conventional therapies (for example, NSAIDs, corticosteroids, DMARDs, methotrexate, or other immunosuppressants) or trial/failure of preferred infliximab products. Typical approval durations are indication-specific (generally up to 12 months for chronic indications; up to 4 doses for certain acute indications).

    • Document prior treatment history (failures, contraindications, or intolerances) and dates/duration of trials.
    • Include prescriber specialty when required (e.g., rheumatologist, gastroenterologist) and dosing consistent with FDA labeling.
    Billing Rule

    Medicare Advantage / Part B Note

    Medicare Advantage members may be subject to Medicare Part B billing rules and Part B step therapy programs. Refer to applicable LCDs/LCAs and Medicare Part B Step Therapy guidance when processing requests for MA members; preferred therapy and Part B step therapy criteria may apply.

    • Medicare may cover outpatient (Part B) infliximab furnished "incident to" a physician's service when not usually self-administered — check LCDs/LCAs.
    • Preferred therapy criteria for Medicare Advantage members: follow Medicare Part B Step Therapy Programs where applicable.
    Note

    Benefit Limitations and Plan-Specific Rules

    Coverage decisions must also be consistent with the member-specific benefit plan. Coverage may be denied if the member's benefit plan excludes experimental/off-label uses or other plan limits apply.

    • Consult the member-specific benefit plan document for exclusions or state mandates that may supersede policy language.

    Biosimilars and Product Preference

    Billing Rule

    Inflectra — preferred infliximab product

    Inflectra (infliximab‑dyyb) is identified as a preferred infliximab product; preferred products (Inflectra and Avsola) are first‑line for coverage and should be used prior to requesting non‑preferred products unless the Preferred Product Criteria are met.

    • Preferred infliximab products: Inflectra and Avsola
    Billing Rule

    Avsola — preferred infliximab product

    Avsola (infliximab‑axxq) is identified as a preferred infliximab product; preferred products (Inflectra and Avsola) are first‑line for coverage and should be trialed before non‑preferred infliximab products unless criteria for non‑preferred use are documented.

    • Preferred infliximab products: Avsola and Inflectra
    Billing Rule

    Infliximab HCPCS codes — billing reference

    Infliximab biosimilars and the reference product are listed with HCPCS codes (J1745, Q5103, Q5104, Q5121); the policy lists biosimilar HCPCS codes alongside J1745 but does not state a separate biosimilar‑specific step beyond the preferred‑product requirements.

    • HCPCS codes: J1745, Q5103, Q5104, Q5121
    Billing Rule

    infliximab‑abda (Renflexis) — billing reference

    Renflexis (infliximab‑abda) is listed among infliximab biosimilars in the policy’s HCPCS/code listings and as an example of a non‑preferred infliximab product requiring justification for use.

    Billing Rule

    infliximab‑axxq (Avsola) — billing reference

    Avsola (infliximab‑axxq) is listed as a biosimilar to Remicade and is identified as a preferred infliximab product in the policy.

    Billing Rule

    Biosimilars similarity to Remicade — billing note

    The policy notes that biosimilars are highly similar to Remicade and share the same FDA‑indicated uses; supporting randomized equivalence studies and prescribing information are cited in the references.

    Note

    Site of Care and Administration

    Note

    Infusion center — site of care

    Infliximab is typically administered as an outpatient intravenous infusion. For Medicare members, outpatient infusions may be covered under Part B when furnished 'incident to' a physician’s service—check Part B rules and applicable LCDs/LCAs.

    • Site of care: outpatient infusion center or physician office per Medicare rules
    Billing Rule

    Infusion center | office — Medicare site‑of‑care billing

    Medicare may cover outpatient (Part B) drugs furnished 'incident to' a physician service if the drug is not usually self‑administered; verify Medicare local coverage guidance and beneficiary plan specifics for site‑of‑care billing.

    Background and Definitions

    Infliximab is a chimeric monoclonal antibody that neutralizes tumor necrosis factor‑alpha (TNF‑alpha) and is used intravenously to treat a range of inflammatory and autoimmune conditions. The policy uses the term "infliximab" to refer to the reference product (Remicade) and FDA‑approved biosimilars (for example, Inflectra, Avsola, Renflexis, CT‑P13/SB2). Biosimilars have been evaluated in randomized trials demonstrating high similarity to the reference product and share the same FDA‑approved indications, and preferred biosimilar products (Inflectra, Avsola) are identified in the policy for first‑line coverage considerations.

    Infliximab — definition
    Definition'Infliximab' refers to all infliximab products (originator and biosimilars).
    IncludesReference product (Remicade) and biosimilars such as Inflectra, Avsola, Renflexis, CT-P13, SB2.
    Benefit routing noteIntravenous infliximab products are handled under the medical benefit unless self-administered subcutaneous formulations are obtained via pharmacy benefit per plan documents.
    Systemic targeted immunomodulator — examples
    DefinitionSystemic targeted immunomodulator — agents listed in policy that should not be combined with infliximab for same indication.
    Examples (selected)adalimumab, certolizumab (Cimzia), etanercept (Enbrel), baricitinib (Olumiant), abatacept (Orencia), upadacitinib (Rinvoq), golimumab (Simponi), tofacitinib (Xeljanz), vedolizumab (Entyvio), mirikizumab (Omvoh), risankizumab (Skyrizi), guselkumab (Tremfya), ustekinumab.
    Policy applicationLists updated across indications; combination therapy with these systemic targeted immunomodulators is prohibited for the same indication per policy.
    Fistula codes (ICD-10)
    Fistula diagnosis codesK60.419, K60.421, K60.422, K60.423, K60.429, K60.50, K60.511, K60.512, K60.513, K60.519, K60.521, K60.522, K60.523, K60.529, K63.2
    Clinical contextCodes cover anorectal, rectal (simple and complex) and intestinal fistulae referenced in policy.
    UseInclude applicable fistula ICD-10 code on prior authorization requests when supporting Crohn's disease or fistulizing disease indications.
    Psoriasis and psoriatic arthropathy codes (ICD-10)
    Psoriasis diagnosis codesL40.0, L40.1, L40.2, L40.3, L40.4, L40.50, L40.51, L40.52, L40.53, L40.54, L40.59, L40.8, L40.9
    ScopeCodes cover plaque psoriasis and psoriatic arthropathies referenced in treatment criteria.
    Provider actionSelect the appropriate psoriasis ICD-10 code when submitting prior authorization for plaque psoriasis or psoriatic arthritis indications.
    Rheumatoid arthritis — ICD-10 codes
    Rheumatoid arthritis codes (selected examples)M05.* (rheumatoid arthritis with rheumatoid factor), M06.* (rheumatoid arthritis without rheumatoid factor), M08.1, plus extensive subcodes (see policy code listings).
    ScopePolicy includes extensive ICD-10 coverage of RA variants, rheumatoid factor status, rheumatoid heart disease/myopathy/polyneuropathy, and related codes.
    Prior auth guidanceInclude the specific RA ICD-10 code from the policy's list when requesting coverage or submitting claims for RA indications.
    Spondylopathy and ankylosing spondylitis codes
    Spondylopathy and ankylosing spondylitis codesM45.0–M45.9 (ankylosing spondylitis by region), M48.8X1–M48.8X9 (other specified spondylopathies by region)
    UseApplied to ankylosing spondylitis eligibility and documentation requirements in the policy.
    Provider actionUse the appropriate spondylopathy/AS code when submitting prior authorization requests for axial spondyloarthropathy indications.
    Infliximab — mechanism
    Mechanism of actionChimeric human/mouse monoclonal antibody against tumor necrosis factor alpha (TNF-alpha) that neutralizes TNF-alpha by binding soluble and transmembrane forms.
    Biologic effectBlocks TNF-alpha binding to receptors, inhibiting interleukin induction, leukocyte migration, and adhesion molecule expression; can mediate lysis of cells expressing transmembrane TNF-alpha.
    Clinical relevanceMechanism underpins efficacy in Crohn's disease, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, psoriatic conditions, and sarcoidosis.
    Infliximab and biosimilars — comparability
    Biosimilar comparabilityRandomized equivalence studies and prescribing information demonstrate that biosimilar infliximab products (e.g., CT-P13, SB2/Avsola/Inflectra) are comparable in efficacy and safety to the reference product.
    Supporting evidenceKey references include PLANETRA and PLANETAS trials and multiple biosimilar prescribing information cited in policy references.
    Policy implicationPolicy treats infliximab to include originator and biosimilars for coverage determinations; Inflectra and Avsola are listed as preferred products.

    Policy Overview and Key Metrics

    multipleIndications with specific criteria listed
    12 monthsTypical max initial/reauthorization period for chronic indications
    J1745,Q5103,Q5104,Q5121Listed HCPCS codes (reference and biosimilars)
    6Indications removed from coverage criteria (per revision)

    Policy Changes and Revision History

    2026-02-01policy_revisionLatest

    Removed coverage criteria for ankylosing spondylitis, Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; replaced references to 'targeted immunomodulator' with 'systemic targeted immunomodulator' and updated lists of systemic targeted immunomodulators across indications.

    2026-02-01clinical_criteria_update

    Updated lists of systemic targeted immunomodulators that must not be used in combination with infliximab and updated lists of prior FDA‑approved systemic targeted immunomodulators for initial therapy (adds include bimzelx, cosentyx, taltz, vedolizumab, mirikizumab, tremfya, zeposia, risankizumab, guselkumab, and others; multiple removals and replacements noted per indication).

    2026-02-01new_requirement

    Added a required diagnosis criterion for immune checkpoint inhibitor–related toxicities and clarified the steroid-failure language to require inadequate improvement despite systemic corticosteroid therapy of adequate dose and duration for the specific severity and diagnosis.

    2026-02-01coding_change

    Removed HCPCS code Q5109 from the policy's listed procedure codes.

    2026-02-01administrative_change

    Removed the Documentation Requirements section and archived the previous policy version 2025D0004AQ.